Oxford Drug Design key facts
as of Oct 2026- Developer of an artificial intelligence-driven drug discovery platform designed to support the identification and development of new therapeutic candidates.
- Oxford Drug Design is valued at approximately $12.7M as of Oct 2026 (last reported valuation).
- It has raised $16.5M; the latest was Later Stage VC ($900K) in Dec 2025.
- Notable investors include Innovate UK, European Commission, SyndicateRoom, University of Oxford, Cambridge Angels — 22 tracked in total.
- Status: Privately Held (backing).
Oxford Drug Design's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·The complete investor list: 22 names
- ·Watch Oxford Drug Design: the Monday email on marks, rounds and moves
Oxford Drug Design funding rounds
No funding rounds for Oxford Drug Design are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Oxford Drug Design
22+Oxford Drug Design valuation
Oxford Drug Design's last reported valuation was $12.7 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
Oxford Drug Design investors
22 investors are on record for Oxford Drug Design, including Innovate UK, European Commission, SyndicateRoom and University of Oxford.
About Oxford Drug Design
Developer of an artificial intelligence-driven drug discovery platform designed to support the identification and development of new therapeutic candidates. The company's platform integrates computational modeling, machine learning, generative molecular design, structure-based and ligand-based methods, and proprietary chemical representations, enabling pharmaceutical and biotechnology organizations to systematically generate, evaluate, and optimize drug candidates with improved feasibility, target relevance, and progression efficiency.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2001
- Employees
- 10
- Website
- oxforddrugdesign.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.